A long-acting FGF21 attenuates metabolic dysfunction-associated steatohepatitis-related fibrosis by modulating NR4A1-mediated Ly6C phenotypic switch in macrophages.
Yue JiYiliang DuanYuanyuan LiQingzhou LuDingkang LiuYifan YangRuilong ChangJing TianWenbing YaoJun YinXiang-Dong GaoPublished in: British journal of pharmacology (2024)
Our results have elucidated the previously unclear mechanisms through which PsTag-FGF21 treats MASH-related fibrosis and identified NR4A1 as a potential therapeutic target for fibrosis.